Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Zhenguang Wang(Beijing Institute of Technology), Weidong Han(Chinese PLA General Hospital)
Cited by 254
Related Papers
LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b
|Journal of Translational Medicine|2015|660
New development in CAR-T cell therapy
|Journal of Hematology & Oncology|2017|409
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
|Journal of Hematology & Oncology|2018|395
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
|Journal of Hematology & Oncology|2020|320
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
|JNCI Journal of the National Cancer Institute|2016|300